MacroGenics to Present Pre-Clinical Data on MGD006 at 26th EORTC-NCI-AACR Symposium

Rockville, MD, Oct. 30, 2014 (GLOBE NEWSWIRE) -- MacroGenics to Present Pre-Clinical Data

on MGD006 at 26th EORTC-NCI-AACR Symposium

ROCKVILLE, Md., October 30, 2014 - MacroGenics,

Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company

focused on discovering and developing innovative monoclonal

antibody-based therapeutics for the treatment of cancer, as well as

autoimmune disorders and infectious diseases, today announced that

it will present pre-clinical data on MGD006 in a poster session at

the 26th EORTC-NCI-AACR Symposium on Molecular Targets

and Cancer Therapeutics taking place in Barcelona, Spain on

November 18-21, 2014. MGD006 is a Dual-Affinity Re-Targeting

(DART ) bi-specific antibody-based molecule that recognizes both

CD123 and CD3 and is being developed for the treatment of

hematological malignancies.

The details of the presentation are as

Session: Immunotherapy (Immune

checkpoints, Vaccination, Oncolytic viruses, Cytokines)

Date: November 19, 2014

Poster Board Number: 132

Abstract Number in Proceedings

Poster Viewing Session: 7:45 am

- 8:00 pm, Poster # 132

Location: Exhibition Hall

Title: "Preclinical activity

and safety of MGD006, a CD123 x CD3 Bispecific DART molecule for

the treatment of hematological malignancies"

MGD006 is a humanized DART molecule that recognizes both CD123

and CD3. The molecule was designed to redirect T cells via their

CD3 component to kill CD123-expressing cells, as shown

pre-clinically. CD123, the Interleukin-3 receptor alpha chain, has

been reported to be overexpressed on malignant cells in a wide

range of hematological malignancies including acute myeloid

leukemia (AML) and myelodysplastic syndrome (MDS). AML and

MDS are thought to arise from a small population of leukemic stem

cells (LSCs) that generally resist conventional chemotherapeutic

agents. LSCs are characterized by high levels of CD123

expression that is low or absent in the corresponding normal

hematopoietic stem cell population. This product candidate is

currently being tested in a Phase 1 clinical study in patients with

relapsed or refractory AML.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company

focused on discovering and developing innovative monoclonal

antibody-based therapeutics for the treatment of cancer, as well as

autoimmune disorders and infectious diseases. The Company generates

its pipeline of product candidates from its proprietary suite of

next-generation antibody-based technology platforms. The

combination of MacroGenics' technology platforms and protein

engineering expertise has allowed the Company to generate promising

product candidates and enter into several strategic collaborations

with global pharmaceutical and biotechnology companies. For

more information, please see the Company's website at

www.macrogenics.com. MacroGenics and DART are registered

trademarks of MacroGenics, Inc.

Cautionary Note on Forward-Looking

Any statements in this press release about future expectations,

plans and prospects for the Company, including statements about the

Company's strategy, future operations, clinical development of the

Company's therapeutic candidates, milestone or opt-in payments from

the Company's collaborators, the Company's anticipated milestones

and future expectations and plans and prospects for the Company and

other statements containing the words "anticipate," "believe,"

"estimate," "expect," "intend," "may," "plan," "predict,"

"project," "target," "potential," "will," "would," "could,"

"should," "continue," and similar expressions, constitute

forward-looking statements within the meaning of The Private

Securities Litigation Reform Act of 1995. Actual results may differ

materially from those indicated by such forward-looking statements

as a result of various important factors, including: the

uncertainties inherent in the initiation and enrollment of future

clinical trials, expectations of expanding ongoing clinical trials,

availability and timing of data from ongoing clinical trials,

expectations for regulatory approvals, other matters that could

affect the availability or commercial potential of the Company's

product candidates and other risk factors described in the

Company's filings with the Securities and Exchange

Commission, including those discussed in the "Risk Factors" section

of the Company's Annual Report on Form 10-K filed with the

Securities and Exchange Commission on March 20, 2014. In

addition, the forward-looking statements included in this press

release represent the Company's views as of the date hereof. The

Company anticipates that subsequent events and developments will

cause the Company's views to change. However, while the Company may

elect to update these forward-looking statements at some point in

the future, the Company specifically disclaims any obligation to do

so. These forward-looking statements should not be relied upon as

representing the Company's views as of any date subsequent to the

Jim Karrels, Vice President, CFO

1-301-251-5172, info@macrogenics.com

Karen Sharma, Vice President

MacDougall Biomedical Communications

1-781-235-3060, ksharma@macbiocom.com